# Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

> **NCT05864742** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 40 (estimated)

## Conditions studied

- Mantle Cell Lymphoma Refractory

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Venetoclax
- **DRUG:** Navitoclax
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05864742
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-07
- **Primary completion:** 2026-06-01
- **Final completion:** 2029-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05864742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05864742, "Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05864742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*